Morgan Stanley
HCWB icon

Morgan Stanley’s HCW Biologics HCWB Stock Holding History

Morgan Stanley’s Portfolio HCWB Stock Details HCWB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14
Closed -$4.77K – 7679
2023
Q1 		$4.77K Hold
14
– – ﹤0.01% 7061
2022
Q4 		$6.52K Hold
14
– – ﹤0.01% 7081
2022
Q3 		$8K Buy
14
+12
+600% +$6.88K ﹤0.01% 7145
2022
Q2 		$1K Hold
2
– – ﹤0.01% 7679
2022
Q1 		$1K Hold
2
– – ﹤0.01% 7842
2021
Q4 		$1K Hold
2
– – ﹤0.01% 7868
2021
Q3 		$2K Buy
+2
New +$2.1K ﹤0.01% 7662

Other funds holding HCWB

HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley's HCWB Position: Q2 2023 in Review

Morgan Stanley sold out of HCW Biologics (HCWB) in Q2 2023, closing a stake of 14 shares — an estimated $4.77K sold.

Morgan Stanley first reported a position in HCWB in Q3 2021 and held it in 7 quarters. The position peaked at $8K in Q3 2022. 12 funds tracked by Wall St. Rank hold HCWB as of Q2 2023.

  • Morgan Stanley reported no remaining HCW Biologics position as of Q2 2023 after selling out during the quarter.
  • Morgan Stanley sold 14 HCW Biologics shares in Q2 2023, an estimated $4.77K.
  • Morgan Stanley first reported a position in HCW Biologics in Q3 2021 and held it in 7 quarters.
  • Morgan Stanley's HCW Biologics position peaked at $8K in Q3 2022.
  • 12 funds tracked by Wall St. Rank held HCW Biologics as of Q2 2023.

Based on Morgan Stanley's 13F filing for Q2 2023, filed 14 Aug 2023.